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Abstract: Background. The majority of ectopic adrenocorti-
cotropic hormone (ACTH)-secreting tumors are localized in the
chest or abdomen. Occasionally, these tumors are found in the
paranasal sinuses.
Methods. We present 2 unusual cases of ectopic ACTH
syndrome whose ACTH-secreting tumors were localized in the
paranasal sinuses and describe their biochemical and radio-
logical presentation.
Results. The first patient had an ACTH-secreting olphactory
neuroblastoma originating in the ethmoid sinuses. The second
patient had a clinical course and biochemical findings indistin-
guishable from pituitary ACTH-dependent Cushing’s syndrome,
except for negative petrosal sinus sampling. Head imaging
showed a ‘‘polyp’’ in the left maxillary sinus-secreting ACTH.
Both patients went into remission following surgical resection
and recovered normal pituitary-adrenal axis function.
Conclusion. Ectopic ACTH secretion may originate from
lesions in the paranasal sinuses. This accessible location allows
for direct immunohistochemical diagnosis with ACTH staining.
Surgical resection/radiation therapy can result in complete
remission of the disease and restoration of normal pituitary-adre-
nal function. VC 2008 Wiley Periodicals, Inc. Head Neck 31:
699–706, 2009
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Ectopic ACTH-secreting tumors are the second
most common etiology of Cushing’s syndrome, af-
ter ACTH-secreting pituitary adenomas.1 In their
typical presentation, and in contrast to pituitary
adenomas, they show rapid development of
symptoms, fewer manifestations of cortisol excess,
frequent manifestations of mineralocorticoid ex-
cess, weight loss, and hyperpigmentation.2 Some
ACTH-secreting bronchial carcinoid tumors, how-
ever, can remain occult for years and the clinical
manifestations develop gradually.3 The diagnostic
challenge is the localization of the tumor. The
usual location is the chest2,4 and the most fre-
quent pathology a bronchial carcinoid responsible
for about 30% of cases. Less frequent pathologies
are thymic carcinoids,5 pancreatic islet cell
tumors,6 pheochromocytomas,7 paragangliomas,8
and medullary thyroid carcinomas.9 Based on
these reported sites, the search usually include
CT or MRI of the chest, abdomen and pelvis,
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octreotide radionuclide scans, and selective ve-
nous sampling for ACTH gradients. Octreotide
scans are sensitive for identifying somatostatin
receptor-expressing tumors, but they are not help-
ful when these receptors are not present.10 Selec-
tive venous sampling procedures, although occa-
sionally useful, may overlook small gradients in
ACTH secretion.11 We report 2 cases of ectopic
ACTH-secreting tumors located in the paranasal
sinuses, highlighting the importance of including
these structures in the search for these tumors.
CASE REPORTS
Case 1. A 48-year-old man was seen with a 3-
week history of progressive malaise, leg edema,
blurred vision, and muscle weakness. He was
severely hypokalemic (serum potassium-2.1
mOsm/L) and had metabolic alkalosis. He had
noted facial swelling and hyperpigmentation for
several moths before his admission. History was
significant for ‘‘chronic sinus congestion’’ treated
with nasal polypectomy 2 years earlier. His weight
had been stable and his blood pressure was nor-
mal. On physical examination, his blood pressure
was 140/70 mm Hg; he had a hyponasal voice, left
lower lung crackles, bilateral axillary lymphade-
nopathy, 11 pitting edema, and onychomycosis in
his toenails. He had decreased proximal muscle
strength. Abnormal laboratory studies included
white count 16,000/mm3 (4000–10,000) with 93%
neutrophils (36–75), serum potassium (2.2 [3.5–
5]) and CO2 (40 mOsm/L [22–34]), calcium 7 mg/
dL (8.6–10.3), phosphorus 1.8 mg/dL (2.7–4.6),
parathyroid hormone (PTH) 153 pg/mL (12–75),
25-hydroxy vitamin D < 6 ng/mL (25–80), and se-
rum albumin 2.4 g/dL (3.5–4.9). Radiographic ex-
amination of the chest revealed minimal left pleu-
ral effusion and faint nodular opacity over the an-
terior portion of the second left rib consistent with
callus surrounding an old fracture as demon-
strated in a subsequent CT scan. The scan also
showed osteopenic-appearing vertebral bodies, 2
small benign-appearing lung nodules, and bilat-
eral nodular enlargement of the adrenal glands.
The adrenal findings led to the measurement of
plasma cortisol of 123.5 lg/dL (7–22), ACTH 648
pg/mL (5–52), and urine-free cortisol of 11,640 lg/
day (20–90). The clinical picture was consistent
with ectopic ACTH-dependent Cushing’s syn-
drome (hyperpigmentation, volume overload,
severe hypokalemia, and leukocytosis), and it was
supported by the very high cortisol levels. For
temporary control, ketoconazole was given in
doses of up to 1 g/day, along with potassium sup-
plements. Cortisol was decreased, symptoms were
improved, and hypokalemia was corrected. A
search for an ectopic ACTH-secreting tumor
included CT of the abdomen and pelvis, which
were negative. A pituitary MRI was obtained to
rule out an atypical ACTH-secreting adenoma.
Although the pituitary gland was normal, a multi-
lobular mass with scattered strong enhancement
was found centered in the ethmoid paranasal
sinuses and extending into the frontal and maxil-
lary sinuses, while the sphenoid sinus was spared.
The mass protruded through the cribriform plate
to the right of midline, pushing the inferior aspect
of the frontal lobe superiorly. The intracranial por-
tion measured 1.8 3 1 cm, whereas the mass in
the paranasal sinuses measured 5 3 9 3 6 cm.
Abnormal enhancement along the inferior frontal
gyrus was suspicious for subarachnoid spread.
The lesion did not involve the orbits, but a mucous
opacity was noted in the maxillary sinuses (Figure
1A). Studies were carried out to characterize this
mass.
To confirm the association of the paranasal
mass with ectopic ACTH secretion, a biopsy from
the nasal cavity portion was performed and dem-
onstrated nested architecture of small round blue
cells with uniform mildly pleomorphism forming
rosettes (Figure 1C) and positive cytoplasmic
staining for ACTH (Figure 1D). Because the
results unequivocally uncovered the source of
ACTH excess, further biochemical diagnostic pro-
cedures, that is, corticotropin-releasing hormone
(CRH) stimulation test or 8-mg dexamethasone
suppression, were not obtained. To search for me-
tastases, an Indium-111 octreotide scan (6 mCi)
was performed, identifying positive tracer local-
ization in the area of the paranasal sinus tumor
(Figure 1B). There were no other focal areas of
increased radiotracer uptake. An abundance of
tumor cells were positive for synaptophysin,
S-100 protein, chromogranin A, and tyrosinase.
The pathology was consistent with an olfactory
neuroblastoma (also known as esthesioneuroblas-
toma). The tumor was surgically exposed via a
frontal approach and a gross total resection was
accomplished. ACTH levels following surgery
decreased (26 pg/mL) but were not completely
suppressed as it would be expected with complete
tumor resection. The patient recovered from sur-
gery and subsequently received adjuvant radio-
therapy. Follow-up over the next 9 months showed
normalization of ACTH and cortisol levels and
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complete suppression (ACTH, <5 pg/mL; cortisol,
1.7 mcg/dL) after 1 mg dexamethasone.
Case 2. A 30-year-old woman was seen with a
3½-year history of a 45-lb weight gain and purple
abdominal striae following pregnancy. She noted
facial fullness, dry skin, acne, easy bruising,
hypertension, fatigue, amenorrhea, cramps in her
hands and feet, facial hirsutism, nocturia, and
occasional ankle edema. She also noted decreased
libido, increased irritability, mood swings, inter-
mittent crying spells, depression, insomnia, short
attention span, and occasional decreased memory.
She complained of right groin pain when bearing
weight or moving her leg. She was gravida-II,
para-II, and had a history of impaired glucose tol-
erance during her pregnancy. Physical examina-
tion revealed truncal obesity, facial fullness,
prominent supraclavicular fullness and buffalo
hump, skin atrophy, pale purple striae in the ab-
domen and thighs, hyperpigmentation of the
knuckles of both hands, acanthosis nigricans in
her neck, tinea versicolor over the neck and lower
back, areas of ecchymosis in her lower extremities
and warts in her fingers. Abnormal laboratory
studies included a white count of 11,000/mm3, and
serum electrolytes were normal. A bone scan to
investigate her hip pain showed a stress fracture
of the right femoral neck. She subsequently frac-
tured her right hip and required open reduction
with internal fixation and capsulorraphy. Her
clinical presentation and physical findings were
FIGURE 1. (A) Case 1 midsagittal MRI view, displaying a multilobular mass (white arrows) in the ethmoid and maxillary paranasal
sinuses, whereas the sphenoid sinus is spared. The mass protrudes through the cribriform plate to the anterior cranial fossa. Arrows
outline the tumor borders. (B) Frontal view of Indium-111 octreotide scan, identifying positive tracer localization in the area of the para-
nasal sinuses (white arrow). (C) Hematoxylin-eosin staining of case 1 paranasal sinus tumor biopsy, demonstrating small round blue
cells with mild pleomorphism forming rosettes (black arrows). (D) Immunoperoxidase (brown) conjugated anti-ACTH antibody immuno-
histochemistry, showing positive cytoplasmic staining for ACTH (bars 5 50 lm).
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FIGURE 2. Case 2. (A) Corticotropin-releasing hormone (CRH) stimulation test, demonstrating a small adrenocorticotropic hormone
(ACTH) response to CRH. (B) CT scan of paranasal sinuses, showing a left maxillary mass. (C) Gross appearance of the sinus
mass during endoscopic resection. (D) Hematoxylin-eosin staining of case 2 maxillary sinus tumor biopsy, demonstrating small round
blue cells. (E) Immunoperoxidase (brown) conjugated anti-ACTH antibody immunohistochemistry, showing positive cytoplasmic staining
for ACTH (bars 5 50 lm).
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consistent with ACTH-dependent Cushing’s syn-
drome, which was confirmed by elevated urine
free cortisol (624 mcg/24 hours) and nonsup-
pressed ACTH (60 pg/mL). Two milligrams of
dexamethasone suppression test failed to achieve
cortisol suppression, whereas 8-mg dexametha-
sone suppression test lowered both cortisol (36 to
10 mcg/dL) and ACTH (40 to 16 pg/mL), sugges-
tive of pituitary ACTH-dependent Cushing’s syn-
drome. This clinical picture was supported by a
CRH stimulation test (Figure 2A) that stimulated
ACTH secretion. In contrast, pituitary MRI was
negative and chest and abdominal CT were also
negative.
Inferior petrosal sinus catheterization showed
no ACTH gradient between petrosal sinus and pe-
ripheral venous blood, suggesting ectopic ACTH
secretion (Table 1). Systemic venous catheteriza-
tion showed a marked step-up in ACTH levels in
the left internal jugular and left angular vein (Ta-
ble 2). A CT scan of the paranasal sinuses showed
a 1-cm mass apposed to the superomedial wall of
the left maxillary antrum (Figure 2B). This mass
was interpreted as a possible benign polyp or mu-
cous retention cyst. Because the result of the ve-
nous sampling suggested the ACTH step-up was
in the vein draining the mass, and the patient
underwent endoscopic resection of this mass
(Figure 2C). The pathology was consistent with a
neuroendocrine tumor (Figure 2D). Immunohisto-
chemistry was positive for ACTH (Figure 2E). Fol-
lowing tumor resection, ACTH levels were com-
pletely suppressed, and the patient underwent
remission of her Cushing’s syndrome. A 3-year fol-
low-up showed that the patient had regained
normal pituitary-adrenal function.
Methods. Urinary-free cortisol and serum corti-
sol were determined by radioimmunoassay using
the Diagnostic Products Corporation kits and
plasma ACTH by the Allegro radioimmunoassay.
MRI was performed using a Tesla-1.5 magnet.
Dexamethasone suppression tests were per-
formed with a low dose (0.5 mg every 6 hours for 8
doses) followed by a high dose (2 mg every 6 hours
for 8 doses). For CRH stimulation, 1 mcg/kg of
CRH was administered intravenously after
obtaining baseline samples; blood samples were
then obtained every 15 minutes for the first hour
and every 30 minutes for the next 2 hours. Inferior
petrosal sinus catheterization and sampling were
carried out under local anesthesia by inserting
catheters into each of the femoral veins at the
groin. Samples for ACTH were obtained simulta-
neously from each inferior petrosal sinus and a pe-
ripheral vein. Systemic venus sampling was car-
ried out by placing a catheter at different levels in
the venous system under fluoroscopic visualiza-
tion. Specifically, samples were obtained from the
left angular vein. Because the systemic venous
sampling followed the inferior petrosal sinus sam-
pling, only 4 sets of baseline samples drawn 5 mi-
nute apart were obtained, and CRH was not
injected to blur peripheral ACTH differences.
ACTH expression by tumor was confirmed by
immunohistochemistry using formalin-fixed par-
affin-embedded 5-mm sections. For case number
1, an anti-ACTH rabbit polyclonal antibody
(DAKO, Carpinteria, CA; catalog no. A0571) was
used at 1:2000 dilution with no antigen retrieval.
Detection of primary antibody was performed
using the avidin–biotin peroxidase method and
3,30-diaminobenzidine (DAB) as a chromogen. For
case number 2, an anti-ACTH rabbit polyclonal
antibody (Ventana Medical Systems, Tuscon, AZ;
catalog no. 760–2506) was used as a prediluted
antibody with CC1 standard pretreatment (pH–
8.0 for 60 minutes). Detection of primary antibody
Table 1. Unstimulated petrosal sinus catheterization and
sampling demonstrating the lack of ACTH gradient between
petrosal sinuses and peripheral venous blood, suggesting
ectopic ACTH secretion.
Sample
Plasma ACTH levels, pg/mL
Left Right Peripheral
I 38 42 44
II 39 47 40
III 54 56 72
IV 45 47 50
Abbreviations: ACTH, adrenocorticotropic hormone.; U17OHC, urinary
17-hydroxycorticosteroids; CRH5corticotropin releasing hormone;
Units: cortisol, mcg/dl.
Table 2. Systemic venous catheterization and sampling
showing a marked ACTH step-up in the left internal jugular
and left angular vein.
Sampling site ACTH, pg/mL
SVC 214
Left mid-innominate 199
Left high-internal jugular 348
Left mid-internal jugular 464
Left low-internal jugular 536
Left angular vein 2880
Peripheral 3 8 sites 111–117
Abbreviation: ACTH, adrenocorticotropic hormone; SVC, superior vena
cava.
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was performed using the avidin–biotin peroxidase
method and DAB as a chromogen. For cell
markers, the following antibodies were used: for
S100, antibodies from Dako-Cytomation at a 1/
250 dilution; for CGA antibodies from Ventana
Medical Systems, and for tyrosinase, antibodies
from Novocastra at a 1/10 dilution. The study was
approved by the institutional review board for
Human Experimentation, and patients gave writ-
ten informed consent.
DISCUSSION
We report 2 cases of Cushing’s syndrome second-
ary to ectopic-ACTH secretion in which the neo-
plasm-secreting ACTH was located in the para-
nasal sinuses. This is a location not usually recog-
nized and may lead to failure of localization and
eventual adrenalectomy for resolution of the
hypercortisolemia. In case 1, the patient lacked
overt symptoms of hypercortisolemia, possibly
because of the relatively rapid progression of the
disease. However, subtle symptoms may have
been present for a longer time but ignored by the
patient. For example, presenting hypocalcemia
and vitamin-D deficiency was likely a result of
Cushing’s syndrome12,13 and strict vegetarian
diet. His complaints of ‘‘nasal stuffiness and sinus
problems’’ were attributed to a prior diagnosis of
nasal polyps and sinusitis. Case 2 presented with
a more indolent course, and both her clinical pre-
sentation and biochemical findings were sugges-
tive of pituitary ACTH-dependent disease. How-
ever, the negative pituitary MRI and inferior pe-
trosal sinus catheterization suggested an ectopic
ACTH source. Although not a common location for
ectopic ACTH syndrome, there are, as we illus-
trate here, ACTH-secreting tumors that originate
from the paranasal sinuses. Other reported ce-
phalic pathologies as a cause of Cushing’s syn-
drome are ectopic pituitary adenomas. These
adenomas derive from normal pituitary tissue
arrested outside the sella turcica in the course of
normal embryonic development14 and as a rem-
nant of the Rathke’s pouch developmental tract.
These clusters of cells are uniformly embedded in
the mucoperiosteum and most commonly located
in the sphenoid bone. Although initially regarded
as an endocrine inactive tissue, it is now recog-
nized that these clusters are composed of a diver-
sity of normal pituitary cells15,16 and have the
capacity to develop a vascular network during the
fourth decade and establish endocrine communi-
cation with the hypothalamus.17 Abnormal prolif-
eration and excessive secretion of pituitary hor-
mones by these rhinopharyngeal pituitary tissues
may be evoked by molecular events that lead to
neoplastic development. Although these rhino-
pharyngeal pituitary tissues can be found in the
normal population, reports of functioning ectopic
pituitary adenomas are uncommon and their pre-
sentation quite variable. They may behave like
ACTH-secreting pituitary adenomas, respond to
suppression with dexamethasone, and because of
their proximity to the pituitary gland petrosal
sinus sampling, give confusing results suggesting
a pituitary source. Alternatively, they may not ex-
hibit the classical dynamic profile of a pituitary
adenoma. Schteingart et al18 reported a patient
with ectopic ACTH syndrome produced by an ade-
noma in the mucosa of the sphenoid tissue. This
patient had a clinical presentation consistent with
pituitary adenoma but failed to respond to metyr-
apone and high-dose dexamethasone, suggesting
an ectopic etiology. Kammer et al19 reported a
patient with ACTH-dependent Cushing’s syn-
drome who suppressed on the high-dose dexa-
methasone test, but pituitary imaging was nega-
tive. A combination of radiation therapy to the pi-
tuitary combined with aminoglutethamide and
metyrapone failed to achieve a sustained remis-
sion. Following bilateral adrenalectomy, there
was continued rise of ACTH and expansion of a
previously ill-defined sphenoid sinus tissue.
Resection of this tissue revealed a chromophobe
adenoma. Suzuki et al20 reported another case of
ectopic pituitary adenoma in the sphenoid sinus
who presented with subtle symptoms of Cushing’s
syndrome for more than a year, resistant to low-
dose dexamethasone suppression test and CRH
stimulation. Radiographic evidence of a tumor
mass in the sphenoid sinus helped localize the
source of ACTH. Although the majority of the
cases involve the sphenoid sinus, others occupy
the cavernous sinus21 and other suprasellar
regions.22 The other types of ectopic ACTH-secret-
ing tumors originating in the paranasal sinuses
are much less frequent but may behave aggres-
sively. Case 2, in this report, behaved both clini-
cally and on dynamic testing like a pituitary ade-
noma, and only the negative pituitary MRI and
inferior petrosal sinus catheterization led to the
search for a nonpituitary ACTH source.
ACTH-secreting olfactory neuroblastomas
have been described only 3 times in the past. One
was a case of ACTH-dependent Cushing’s syn-
drome that failed to stimulate with CRH or sup-
press with a high dose of dexamethasone. This
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patient presented with florid Cushing’s syndrome
along with hypertension and severe hypokalemia.
Petrosal sinus sampling was positive for an ACTH
step-up, but the pituitary MRI was negative. The
patient responded to metyrapone, but repeated
imaging after 10 months identified an olfactory
neuroblastoma in the ethmoid sinus. The tumor
was surgically excised and treated with adjuvant
radiation therapy, but it reappeared in the maxil-
lary sinus and was finally fully resected. Arnesen
et al24 reported a patient presenting with florid
Cushing’s syndrome who had a ‘‘nasal polyp’’
consistent with an olfactory neuroblastoma that
immunostained positive for ACTH. Yu et al25
reported a patient with florid Cushing’s syndrome
with negative body cross-sectional imaging stud-
ies. An ACTH-secreting olfactory neuroblastoma
extending to the cranium was identified by both
positive emission tomography and octreotide
scan. Hypercortisolemia was initially controlled
by metyrapone and external beam radiation.
Although ACTH-secreting olfactory neuroblas-
tomas are extremely rare, nonsecreting tumors are
also uncommon. Thus far, only 1000 cases have
been described who, like case 1, presented mainly
with nasal congestion.26 The prognosis of these
malignant tumors is relatively poor with a 5-year
survival rate of 45% to 70%.27 The treatment
approach consists of extensive resection and radia-
tion therapy, followed by resection of recurrent dis-
ease. The recurrence rate is high and tends to
involve the maxillary sinuses and neck lymph
nodes and may occur after a decade.28,29 The previ-
ous 2 cases of ACTH-secreting olfactory neuroblas-
toma had a favorable outcome of at least 5 years,
probably because the clinical manifestations of
Cushing’s syndrome led to an earlier diagnosis and
treatment. It is also possible that the ability to syn-
thesize and secrete ACTH required a more differ-
entiated and less aggressive tumor biology.23,24
Other rare paranasal and cranial ACTH-secreting
neuroendocrine tumors,30–32 as well as 1 case of
ACTH-secreting nasopharyngeal carcinoma33 and
meningioma,34 have been described.
In summary, we present 2 cases of ectopic
ACTH syndrome, in which the source of ACTH
was in the paranasal sinuses. The cases illustrate
the variegated clinical phenotype of the syn-
drome, ranging from the classical description with
rapid onset and progression, minimal manifesta-
tions of hypercortisolism, high ACTH and cortisol
levels, and pronounced hypokalemia to the more
indolent clinical course, which resembles clini-
cally and biochemically classical pituitary ACTH-
dependent disease. Case 1 followed the first pat-
tern, whereas case 2 illustrates the latter. Given
a patient with ACTH-dependent Cushing’s syn-
drome, the following findings should prompt a
more careful investigation for paranasal location
of an ectopic ACTH source: (1) a normal pituitary
MRI, (2) negative or inconclusive inferior petrosal
sinus catheterization, (3) negative imaging of the
chest and abdomen, and (4) symptoms or imaging
findings of paranasal pathology.
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